Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emricasan in NASH Cirrhosis and Severe Portal Hypertension
NCT02960204Phase 2Completed
- Sponsor
- Histogen Inc.
- Start
- Oct 2016
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of emricasan in Nonalcoholic steatohepatitis (NASH), Liver cirrhosis (LC) and Portal Hypertension (PH) (4 arms), sponsored by Histogen Inc. Primary endpoint: Hepatic Venous Pressure Gradient at 24 weeks. Started Oct 2016; status: completed.
02
Drugs
emricasan
03
Conditions
Nonalcoholic steatohepatitis (NASH)Liver cirrhosis (LC)Portal Hypertension (PH)
Beyond the preview
Go deeper on NCT02960204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02960204.